Sanofi(SNY)
PARIS, France
Pharmaceutical1 H-1B visas (FY2023)Focus: Small Molecules, Biologics
Sanofi is a life sciences company focused on Small Molecules, Biologics.
ImmunologyOncologyNeurologyRare DiseasesVaccines
Funding Stage
PUBLIC
Employees
91,000
Open Jobs
1126
Products & Portfolio (16)
34 discontinued products not shown
ADLYXIN
lixisenatide
Peak
PeptideSUBCUTANEOUS · SOLUTION
100/33 SOLIQUA 100/33 is a combination of insulin glargine, a basal insulin analog, and lixisenatide, a GLP-1 receptor agonist. Insulin glargine The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis and enhances protein synthesis. Lixisenatide Lixisenatide is a GLP-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.
type 2 diabetes mellitus
2016
30
ADMELOG
insulin lispro
Peak
INTRAVENOUS, SUBCUTANEOUS · SOLUTION
analogs, including insulin lispro products. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.
glycemic control in adult
2017
30
ADMELOG SOLOSTAR
insulin lispro
Peak
SUBCUTANEOUS · SOLUTION
analogs, including insulin lispro products. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.
glycemic control in adult
2017
30
ALLEGRA ALLERGY
fexofenadine hydrochloride
LOE Approaching
ORAL · TABLET
hivesrelieves itching due to hives (urticaria)an allergic skin reaction from occurring
2000
30
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION
fexofenadine hydrochloride and pseudoephedrine hydrochloride
LOE Approaching
ORAL · TABLET, EXTENDED RELEASE
these symptoms due to hay feverother upper respiratory allergies: ▪ runny nose ▪ sneezing ▪ itchywatery eyes ▪ itching of the nose+4 more
1997
30
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION
fexofenadine hydrochloride and pseudoephedrine hydrochloride
LOE Approaching
ORAL · TABLET, EXTENDED RELEASE
these symptoms due to hay feverother upper respiratory allergies: ▪ runny nose ▪ sneezing ▪ itchywatery eyes ▪ itching of the nose+4 more
2004
30
APIDRA
insulin glulisine
LOE Approaching
INTRAVENOUS, SUBCUTANEOUS · INJECTABLE
analogs, including insulin glulisine. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.
glycemic control in adult
2004
30
APIDRA SOLOSTAR
insulin glulisine
LOE Approaching
SUBCUTANEOUS · INJECTABLE
analogs, including insulin glulisine. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.
glycemic control in adult
2004
30
ARAVA
leflunomide
LOE Approaching
ORAL · TABLET
(a mitochondrial enzyme involved in de novo pyrimidine synthesis) and has antiproliferative activity. Several in vivo and in vitro experimental models have demonstrated an anti-inflammatory effect.
rheumatoid arthritis
1998
30
AUBAGIO
teriflunomide
Peak
ORAL · TABLET
Dihydroorotate Dehydrogenase Inhibitors
relapsing forms of multiple sclerosis (MS)to include clinically isolated syndromerelapsing-remitting disease+2 more
2012
0
AVAPRO
irbesartan
LOE Approaching
ORAL · TABLET
Angiotensin 2 Receptor Antagonists
hypertensionto lower blood pressurediabetic nephropathy in patients with type 2 diabetes+3 more
1997
30
CAMPATH
alemtuzumab
LOE Approaching
mAbINTRAVENOUS · VIAL
CD52-directed Antibody Interactions
leukemia
2001
30
Pipeline & Clinical Trials
Efluelda® Pre-filled syringe
Influenza ImmunizationClinical Trials (1)
NCT07282795Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
N/AInvestigational Procedures
Sphingomyelin LipidosisClinical Trials (1)
NCT04106544A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)
N/Aswab sampling
Influenza, HumanClinical Trials (1)
NCT04244500Burden of Influenza at Emergency Department (ED) Level in European Countries
N/AInsulin
Type 1 DiabetesClinical Trials (5)
NCT00474838Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy
Phase 4NCT00489190APIDRA Registration Study
Phase 4NCT00911625Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Phase 4+2 more
Kidney Information Network for Disease Research and Education
ESRDClinical Trials (1)
NCT03321604Kidney Information Network for Disease Research and Education
N/AObservatory on Elderly Patients "Les S.AGES"
Diabetes Mellitus, Type 2Clinical Trials (1)
NCT01065909Observatory on Elderly Patients "Les S.AGES"
N/AAnalysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registr
Acute LeukemiaClinical Trials (2)
NCT01362985Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor
N/ANCT01362972Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor
N/ASwiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Optic Neuritisa live attenuated chimeric JE vaccine
Japanese EncephalitisClinical Trials (2)
NCT02526550Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX
Phase 4NCT02602652Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine
N/ARetrospective Safety Survey In Patients Included In NV1FGF Clinical Trials
Peripheral Arterial Occlusive DiseaseClinical Trials (1)
NCT01135797Retrospective Safety Survey In Patients Included In NV1FGF Clinical Trials
N/ABevacizumab
Lung CancerClinical Trials (5)
NCT00116506Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer
Phase 2NCT00881504A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma
Phase 2NCT05584670A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Phase 1/2+2 more
AZD6244
Thyroid CancerFlublok Quadrivalent influenza vaccine RIV4
InfluenzaClinical Trials (1)
NCT04460781Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring
N/ADUPIXENT®
AsthmaClinical Trials (2)
NCT04287621Registry of Asthma Patients Initiating DUPIXENT®
N/ANCT06099704Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
N/ARIAT Registry: Reason for Not Intensifying Antihypertensive Treatment
HypertensionClinical Trials (1)
NCT00258921RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment
N/AMenactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
MeningitisClinical Trials (1)
NCT01689155Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children
N/APlerixafor
Bone Marrow / Autologous TransplantsClinical Trials (1)
NCT01738373Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation
N/AObservational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
Prostatic NeoplasmsClinical Trials (1)
NCT01076751Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
N/ADupilumab - Standard Dose
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)Clinical Trials (1)
NCT06892704Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
N/AA Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatmen
AsthmaClinical Trials (1)
NCT05070663A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)
N/ANasopharyngeal sampling
Bordetella Pertussis, Whooping CoughClinical Trials (1)
NCT03388034Pertussis Immunization Programs in Low Income Countries - Ivory Coast
N/ASepraspray
Adhesion PreventionClinical Trials (3)
NCT00813397Manageability and Safety Assessment of Sepraspray in Abdominal Surgery.
N/ANCT00778479Evaluation of the Safety of Sepraspray in Open Abdominal Surgery
N/ANCT00624390Sepraspray™ Laparoscopic Myomectomy Study
N/ABrigham and Women's Rheumatoid Arthritis Sequential Study
Rheumatoid ArthritisAlglucosidase alfa GZ419829
Glycogen Storage Disease Type IIClinical Trials (1)
NCT04848779A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
N/AOlipudase alfa
Acid Sphingomyelinase Deficiency (ASMD)Clinical Trials (5)
NCT02004691Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Phase 2/3NCT02004704A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Phase 2NCT06949358A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France
Phase 2+2 more
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 m
Primary Hypercholesterolaemia and Mixed DyslipidaemiaClinical Trials (1)
NCT05129241Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector
N/AA Screening Study Evaluating Disease Status of Gaucher Type I Patients
Gaucher Disease, Type 1Clinical Trials (1)
NCT00795197A Screening Study Evaluating Disease Status of Gaucher Type I Patients
N/AAlemtuzumab
Leukemia, B-Cell, ChronicClinical Trials (1)
NCT00344825Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)
N/ABlood sampling
Septic ShockClinical Trials (2)
NCT02638779REAnimation Low Immune Status Markers
N/ANCT00929318Influence of Thyroid Hormones on the Woundhealing Process
N/AFibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease
Fabry DiseaseClinical Trials (1)
NCT06325488Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease
N/Aintradermal pholcodine allergy test in cases
Neuromuscular Blocking Agents AnaphylaxisPatterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients
Medication Non-adherenceClinical Trials (1)
NCT00998127Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients
N/AInsulin glargine
DiabetesClinical Trials (1)
NCT03703869Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.
N/AGaucher disease DNA mutation analysis
Gaucher DiseaseClinical Trials (1)
NCT02785744Genzyme Osteopenia/Osteoporosis Study
N/ADigital Gaucher Platform
Gaucher DiseaseClinical Trials (1)
NCT04997772Digital Health Platform Customized for Patients With Gaucher Disease
N/AUnderstanding MRI in MS
Multiple SclerosisClinical Trials (1)
NCT03872583Understanding Magnetic Resonance Imaging in Multiple Sclerosis
N/Adupilumab
Eosinophilic Esophagitis (EoE)Clinical Trials (1)
NCT06693531A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
N/Ainsulin Glargine + Insulin Apidra
Diabetes Type 1Clinical Trials (1)
NCT00925977Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents
N/AHeparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
Heparin-induced ThrombocytopeniaClinical Trials (1)
NCT00748839Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
N/AT1 Weighted MRI
MyelofibrosisClinical Trials (1)
NCT01973881Quantitative MRI for Myelofibrosis
N/AGlucommander
Diabetes or With New HyperglycemiaClinical Trials (1)
NCT00394524Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU
N/AAwareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer
OsteoporosisClinical Trials (1)
NCT00816452Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer
N/AALIROCUMAB SAR236553
HypercholesterolemiaClinical Trials (1)
NCT03379558Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study
N/ADocetaxel
Ovarian NeoplasmsClinical Trials (1)
NCT00452985Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer
N/ANon-interventional Translational Study in Mild, Moderate and Severe Acne Patients
AcneClinical Trials (1)
NCT07411638Non-interventional Translational Study in Mild, Moderate and Severe Acne Patients
N/AAMD3100 + G-CSF
Autologous Stem Cell TransplantClinical Trials (1)
NCT00291811Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization
N/ATZIELD
Type 1 DiabetesClinical Trials (1)
NCT06481904Registry for Stage 2 Type 1 Diabetes
N/Adocetaxel + CEF
CYP3A PhenotypingClinical Trials (1)
NCT01110291Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events
N/AScreening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patie
Pompe DiseaseClinical Trials (1)
NCT00113035Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease
N/AVenous Thromboembolism Taskforce Audit Program
Venous ThrombosisClinical Trials (1)
NCT00535171Venous Thromboembolism Taskforce Audit Program
N/AOpen Jobs (1126)
Clinical Operations Study Country Lead (COSCL)
Tokyo
Clinical OperationsYesterday
Computerized System Validation Engineer
Zeralda
Quality2d ago
Head of Automation& Manufacturing Systems
Zeralda
Manufacturing2d ago
糖尿病事业部-医学信息沟通代表-杭州
Hangzhou
2d ago
Computational Scientist - Bioinformatician
Cambridge, MA
Data Science & AI3d ago
$122K - $177K/yr
Digital R&D Veeva CoE Lead
Hyderabad
Research & Development3d ago
疫苗事业部-区域市场经理-西安
Xian
4d ago
Medical - Real-World Evidence Data Scientist - Shanghai
Shanghai
Data Science & AI4d ago
Medical - Real-World Evidence Data Scientist - Beijing
Beijing
Data Science & AI4d ago
Medical - Manager, Real World Investigator-Shanghai
Shanghai
4d ago
Medical - Manager, Real World Investigator - Shanghai
Shanghai
4d ago
特药事业部-医学信息沟通代表-广州
Guangzhou
4d ago
特药事业部-医学信息沟通代表-南充
Nanchong
4d ago
M&S-QC Analyst Physico Chemistry-Beijing
Beijing
Manufacturing4d ago
Global Medical Product Lead
Morristown, NJ
4d ago
$179K - $258K/yr
Biologics Operations Summer Intern
Waterford
Manufacturing4d ago
Director - Medical Portfolio Strategy & Solutions
Cambridge, MA
Business Development4d ago
$206K - $298K/yr
Field Medical Director, Oncology East
Cambridge, MA
Medical Affairs4d ago
$206K - $298K/yr
Privacy Officer and Counsel
Morristown, NJ
4d ago
$179K - $258K/yr
Platform Engineer
Toronto, ON
Engineering4d ago
Technicien de Conditionnement et Contrôle (2x7h)
Montpellier
4d ago
Manufacturing Summer Student
Waterford
Manufacturing4d ago
Director, Commercial Transformation
Cambridge, MA
Commercial4d ago
$161K - $233K/yr
Data and AI Engineering Manager - Core Digital Products
Toronto, ON
Engineering4d ago
$125K - $209K/yr
Commercial Lead EP
Buenos Aires
Commercial4d ago
Interview Prep Quick Facts
Portfolio: 194 approved products, 162 clinical trials
Top TAs: Oncology, Metabolic Diseases, Infectious Diseases
H-1B (2023): 1 approval
Publications: 25 in PubMed
Open Roles: 1126 active jobs
Portfolio Health
Pre-Launch31 (16%)
Launch2 (1%)
Growth2 (1%)
Peak20 (10%)
LOE Approaching123 (63%)
Post-LOE16 (8%)
194 total products
Therapeutic Area Focus
Oncology
8 marketed749 pipeline
Metabolic Diseases
15 marketed396 pipeline
Infectious Diseases
5 marketed359 pipeline
Rare Diseases
5 marketed152 pipeline
Neurology
4 marketed143 pipeline
Cardiovascular
7 marketed103 pipeline
Respiratory
13 marketed93 pipeline
Immunology
7 marketed70 pipeline
Marketed
Pipeline
Hiring Trend
Actively Hiring
1126
Open Roles
+1126
Added
-0
Filled/Removed
Based on last 2 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub